275 related articles for article (PubMed ID: 19378738)
1. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
3. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
4. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
5. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric and radiobiological investigation of permanent implant prostate brachytherapy based on Monte Carlo calculations.
Haidari AM; Miksys N; Soubiran P; Cygler JE; Holmes O; Perry G; Thomson RM
Brachytherapy; 2019; 18(6):875-882. PubMed ID: 31400953
[TBL] [Abstract][Full Text] [Related]
7. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
8. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
9. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
10. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
11. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
[TBL] [Abstract][Full Text] [Related]
13. Potential role of various dosimetric quality indicators in prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
16. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric and radiobiological comparison of TG-43 and Monte Carlo calculations in
Peppa V; Pappas EP; Karaiskos P; Major T; Polgár C; Papagiannis P
Phys Med; 2016 Oct; 32(10):1245-1251. PubMed ID: 27720277
[TBL] [Abstract][Full Text] [Related]
18. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
19. The impact of edema on planning 125I and 103Pd prostate implants.
Yue N; Dicker AP; Nath R; Waterman FM
Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
[TBL] [Abstract][Full Text] [Related]
20. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
